Taysha Gene Therapies Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	5.49	9.77	8.33	15.45	2.5	-
Revenue Growth	-32.27%	17.28%	-46.07%	517.55%	-	-
Gross Profit	5.49	9.77	8.33	15.45	2.5	-
Selling, General & Admin	38.94	33.87	28.95	30.05	37.36	41.32
Research & Development	123.14	86.4	66	56.78	91.17	131.94
Operating Expenses	158.64	120.27	94.95	86.83	128.53	173.27
Operating Income	-153.16	-110.5	-86.62	-71.37	-126.03	-173.27
Interest Expense	-0.04	-0.06	-0.1	-5	-3.8	-1.43
Interest & Investment Income	10.95	9.22	6.94	3.57	0.25	0.17
Other Non Operating Income (Expenses)	-1.21	-1.49	-0.09	-34.77	-0.02	-
EBT Excluding Unusual Items	-143.47	-102.83	-79.88	-107.57	-129.59	-174.52
Asset Writedown	-	-	-4.84	-1.07	-36.42	-
Other Unusual Items	-6.17	-6.17	-4.58	-2.94	-	-
Pretax Income	-149.63	-109	-89.3	-111.57	-166.01	-174.52
Net Income	-149.63	-109	-89.3	-111.57	-166.01	-174.52
Net Income to Common	-149.63	-109	-89.3	-111.57	-166.01	-174.52
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	362	320	250	116	44	38
Shares Outstanding (Diluted)	362	320	250	116	44	38
Shares Change	31.09%	27.82%	115.41%	164.20%	16.74%	113.13%
EPS (Basic)	-0.41	-0.34	-0.36	-0.96	-3.78	-4.64
EPS (Diluted)	-0.41	-0.34	-0.36	-0.96	-3.78	-4.64
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-132.57	-93.83	-81.6	-76.89	-109.01	-132.35
Free Cash Flow Per Share	-0.37	-0.29	-0.33	-0.66	-2.48	-3.52
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	-2792.32%	-1130.65%	-1039.49%	-461.94%	-5037.05%	-
Profit Margin	-2728.04%	-1115.27%	-1071.62%	-722.06%	-6635.25%	-
Free Cash Flow Margin	-2416.99%	-960.07%	-979.23%	-497.62%	-4356.88%	-
EBITDA	-151.99	-109.35	-85.38	-70	-124.86	-172.78
D&A For EBITDA	1.17	1.15	1.25	1.37	1.17	0.49
EBIT	-153.16	-110.5	-86.62	-71.37	-126.03	-173.27

SEC Filings: 10-K · 10-Q